Expand SMMT Menu
SMMT MENU

SMMT Latest Press Releases

-- June 9, 2026 --

Summit Therapeutics Announces Proposed Public Offering of Common Stock Business Wire 4:47 PM

-- June 4, 2026 --

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference Business Wire 4:30 PM

-- May 31, 2026 --

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Business Wire 9:06 AM

-- May 30, 2026 --

Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 Business Wire 8:00 AM

-- May 14, 2026 --

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology Globe Newswire 9:15 AM

-- May 4, 2026 --

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 9:23 AM

-- April 30, 2026 --

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026 Business Wire 4:32 PM

-- March 27, 2026 --

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 Business Wire 8:15 AM

-- February 26, 2026 --

Summit Therapeutics to Present at Upcoming Investor Conferences Business Wire 6:45 PM

-- February 23, 2026 --

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 Business Wire 4:05 PM

-- February 17, 2026 --

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 Business Wire 5:05 PM

-- February 11, 2026 --

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight PRNewswire 5:31 PM

-- January 30, 2026 --

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- January 29, 2026 --

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy Business Wire 7:30 AM
Market Data Delayed 15 Minutes